Among the 55 ICI‐associated SJS/TEN cases with available information on treatment, systemic treatment with corticosteroid was the most commonly chosen method (56.4% of cases), followed by a combination of corticosteroid with intravenous immunoglobulin (IVIg) (12.7% of cases), cyclosporine (10.6% of cases), and tumor necrosis factor (TNF) inhibitors (10.6% of cases) (Figure 3a). Here, TNF is linked to Schwartz-Jampel syndrome.